GlassScriptPhysician profile
Kirk Kinberg
NPI 1316909260
$5,170.07
in general payments reported to CMS, 2019-2025
30 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $179 · 2021: $338 · 2022: $533 · 2023: $694 · 2024: $2,173 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,143 · Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,142.92 |
| Food and Beverage | $1,839.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Consortium of Independent Immunology Clinics, LLC | $2,142.92 | 2024-2025 | |
| Genzyme Corporation | $686.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $395.84 | 2019-2025 | Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $269.11 | 2021-2025 | |
| Pfizer INC. | $253.93 | 2019-2025 | |
| Abbvie INC. | $154.45 | 2022-2023 | |
| Glaxosmithkline, LLC. | $147.30 | 2019-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $138.19 | 2020-2024 | Hyqvia, Cuvitru |
| Hospira, INC. | $126.11 | 2024-2025 | |
| Amgen INC. | $98.52 | 2022-2023 | Tezspire |
| Genentech USA, INC. | $84.61 | 2021-2022 | |
| Csl Behring | $78.79 | 2021-2025 | Hizentra |
| Grifols USA, LLC | $67.77 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Biocryst US Sales Co., LLC | $65.67 | 2021-2023 | Orladeyo |
| Leo Pharma INC. | $63.73 | 2022-2025 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.75 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Optinose US, INC. | $41.80 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $39.01 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $38.76 | 2019-2020 | |
| Horizon Therapeutics Plc | $31.35 | 2021 | |
| Octapharma USA, INC. | $29.74 | 2022 | |
| Pharming Healthcare, INC. | $28.73 | 2021-2023 | Ruconest |
| Kaleo, INC. | $24.00 | 2019-2021 | |
| Bio Products Laboratory USA, INC. | $23.60 | 2023 | Coagadex, Gammaplex |
| Organon LLC | $21.16 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $16.21 | 2025 | Zoryve |
| Shire North American Group INC | $13.61 | 2019 | |
| Alk-Abello, INC | $12.31 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $11.93 | 2020 | |
| Cycle Pharmaceuticals INC | $8.39 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,878.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Kinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.